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Abstract (193 words) 
Objective: To test the hypothesis that adjunctive inhaled NO would improve RV function and viability in 
acute PE. Methods: This was a  randomized, placebo-controlled, double blind trial conducted at four 
academic hospitals. Eligible patients had acute PE without systemic arterial hypotension but had RV 
dysfunction and a treatment plan of standard anticoagulation. Subjects received either oxygen plus 50 
parts per million nitrogen (placebo) or oxygen plus 50 ppm NO for 24 hours.  The primary composite 
endpoint required a normal RV on echocardiography and a plasma troponin T concentration <14 pg/mL. 
The secondary endpoint required a blood brain natriuretic peptide concentration < 90 pg/mL and a Borg 
dyspnea score <=2. The sample size of N=76 tested if 30% more patients treated with NO would achieve 
the primary endpoint with 80% power and alpha=5%.  Results: We randomized 78 patients and after two 
withdrawals, 38 were treated per protocol in each group. Patients were well matched for baseline 
conditions. At 24 hours, 5/38 (13%) of patients treated with placebo and 9/38 (24%) of patients treated 
with NO reached the primary endpoint (P=0.375). The secondary endpoint was reached in 34% with 
placebo and 13% of the NO (P=0.11). In a pre-planned post-hoc analysis, we examined how many 
patients with RV hypokinesis or dilation at enrollment resolved these abnormalities; 29% more patients 
treated with NO resolved both abnormalities at 24 hours (P=0.010, Cochrane’s Q test). Conclusions: In 
patients with severe submassive PE, inhaled nitric oxide failed to increase the proportion of patients with 
a normal troponin and echocardiogram but increased the probability of eliminating RV hypokinesis and 
dilation on echocardiography. 
.  
Clinical trial registration NCT01939301 
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Abbreviations 
BNP-brain natriuretic peptide 
CT-computed tomography 
FAC-fractional area of contraction 
LV-left ventricle 
PE-pulmonary embolism 
PEmb QoL- pulmonary embolism quality of life survey 
RIMP-right ventricular index of myocardial performance 
SF 36-standard form 36 quality of life survey 
TAPSE-tricuspid annual plane systolic excursion 
NO-nitric oxide 
RV-right ventricle 
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Introduction  
Acute pulmonary embolism (PE) causes direct thrombotic occlusion of pulmonary arteries, which 
increases pulmonary vascular resistance and right ventricular (RV) afterload, ultimately causing RV 
contractile dysfunction and inflammatory damage.[1, 2] As a result, PE impairs RV contraction on 
transthoracic echocardiography, and produces elevated circulating cardiac troponin proteins and brain 
natriuretic peptides (BNP).[3] Severe RV afterload and dysfunction clearly increases the risk of death and 
contributes to ventilation-perfusion abnormalities that cause dyspnea and hypoxemia, which may be long-
lasting.[4-7]  
The rationale for an inhaled vasodilator as a treatment for PE stems from evidence that non-mechanical 
processes contribute to increased pulmonary vascular resistance. The percentage of radiographically-
evident pulmonary thrombotic vascular occlusion often fails to predict severity of RV dysfunction, 
biomarker abnormalities and clinical outcome.[6, 8, 9] Acute PE triggers pulmonary vasoconstriction, 
platelet hyperactivation and microvascular obstruction, caused in part by reduced nitric oxide availability 
to the pulmonary vasculature.[10-12] Drugs that increase cyclic guanosine monophosphate, such as 
inhaled NO, acutely decrease pulmonary arterial pressures in experimental models of hemolysis- and PE-
induced pulmonary hypertension as well as in patients with chronic pulmonary hypertension.[13-16] 
Several case reports and a small, non-randomized clinical trial of PE showed temporal improvement in 
dyspnea from PE with NO treatment.[15, 17]  
We therefore hypothesized that inhaled NO would reduce both RV dysfunction and injury from acute PE 
seen on echocardiography and high precision plasma troponin concentrations, respectively. Our 
secondary aim tested if inhaled NO would reduce RV strain, evidenced by a reduction in BNP and patient 
perception of dyspnea. 
Study design 
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The inhaled Nitric Oxide for Pulmonary Embolism (iNOPE) trial was a multicenter randomized, double-
blind, controlled trial of inhaled NO + oxygen versus nitrogen + oxygen in subjects with acute PE with 
normotension but with RV dysfunction (intermediate risk or submassive PE). The iNOPE protocol and 
methods have been described in detail and the trial was registered on clinicaltrials.gov 
(NCT01939301).[18] The protocol was approved by the Institutional Review Boards at participating 
centers.  
Funding 
The trial was sponsored by the National Institutes of Health (UM1HL113203-01) and by an investigator 
initiated grant from Mallinckrodt Pharmaceuticals and Roche Diagnostics in 2015. The sponsors had no 
role in the protocol design, data analysis or manuscript writing. 
Patient selection 
All patients were >17 years old, normotensive, had image-proven proximal PE and were intermediate-
high risk using the European Society of Cardiology definition (sPESI≥1 and RV dysfunction).[19] The 
definition of image proven was a filling defect suggestive of acute PE in a contrast-enhanced pulmonary 
artery.  RV dysfunction was defined by an elevated BNP (>90 pg/mL) or troponin I (>0.1 ng/mL), and 
evidence of RV dilation (RV >42 mm in diastole, or RV:LV ratio >1.0 on CT scan measured as part of 
usual care by a board certified radiologist who was not affiliated with the study) or RV hypokinesis on 
echocardiography.[6, 19] Exclusions included pregnancy, vasopressor use, inability to tolerate a nasal 
cannula, altered mental status, written plan to not administer anticoagulation, written plan for fibrinolysis, 
and the use of drugs known to increase cyclic guanosine monophosphate.  
Treatment protocol 
All patients received treatment doses of either unfractionated or low molecular weight heparin. 
Antiplatelet drugs were discontinued. Study drug or placebo was administered with a commercially 
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available, FDA-cleared device (Inovent,® Mallinckrodt Pharmaceuticals, Clinton, NJ). Blinded canisters 
of NO or placebo were supplied by Mallinckrodt. The method of randomization and blinding, blood 
collection and echocardiography has been described in detail.[18] NO or nitrogen placebo was titrated at 
2 ppm/min over 25 min to a dose of 50 ppm via nasal cannula, which was maintained for 24 hours.  The 
rationale for the 2 ppm per minute titration and weaning rate was based upon considerations of patient 
safety versus the potential feasibility and generalizability of the protocol. As previous described,, we 
believed the 2 ppm per minute rate of change allowed research personnel enough time to observe the 
patient for changes (symptoms and vital signs), but would not excessively prolong the protocol.[18] After 
24 hours (+/- 3h) of treatment, the NO or nitrogen was weaned at 2ppm per minute to 0 ppm NO over 25 
min. To investigate integrity of blinding, the research coordinator asked the primary physician in charge 
of the patient’s care during hospitalization for his or her opinion whether the patient received NO or 
Placebo. 
Patient safety concerns 
Vital signs and methemoglobin, carboxyhemoglobin with a Masimo Rainbow® Cooximeter device 
(Masimo Corporation, Irving, CA), were monitored hourly. An unblinding envelope and emergency 
treatment algorithm were posted at the bedside to inform the healthcare team how to handle acute 
deterioration.  
Study measurements 
The Borg dyspnea score (0-10) was measured hourly. A study-funded transthoracic Doppler-
echocardiogram was performed after weaning NO, always within 3 hours. All patients had blood 
specimensdrawn for troponin, BNP and nitrate measurements within one hour of starting NO at baseline 
and then immediately prior (< 1 hour in all cases) to weaning, 24 hours later.  Plasma concentrations of 
nitrite and nitrate were measured with high performance liquid chromatography (EiCOM ENO-30, San 
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Diego, CA); troponin T (TnT) was measured with a high precision instrument (Roche COBAS, e411, 
Indianapolis, IN) and BNP was measured with iSTAT, (Abbott, Princeton, NJ).  
Outcome measurements 
The primary efficacy outcome was normal RV function on echocardiography and a TnT concentration 
<14 pg/mL[3] at 24 hours. Normal RV function required normal RV size (<42 mm in diastole) and 
tricuspid annular plane systolic excursion (TAPSE) >16 mm and normal right ventricular index of 
myocardial performance (RIMP) (<0.40 using spectral Doppler or < 0.55 using tissue Doppler) and 
normal fractional area of contraction (FAC) (>33%);  All echocardiograms, including those obtained at 
enrollment, were read by a cardiologist and echocardiography expert (author RAM) who was blinded to 
group assignment. Missing echocardiographic parameters were analyzed as if they were normal. The 
secondary efficacy outcome required a Borg dyspnea score ≤2  and a BNP level <90 pg/mL.  We also 
measured mortality rate and perceived perception of wellness with a standardized survey at 3 months after 
treatment (via SF36 and PEmb QoL).[20] Lastly, we a preplanned secondary analysis, assessed the 
frequency of resolution of two commonly measured abnormalities on echocardiography, RV hypokinesis 
and dilation. We compared the proportion of patients between treatment groups who had neither 
abnormality at 24 hours, and we compared the frequency with which each treatment was associated with 
resolution of both RV hypokinesis and dilation (i.e., conversion from having one or both abnormalities at 
diagnosis to having neither at 24 hours).   
Sample size and analytical methods 
The minimum sample size of N=72 treated per protocol was predicated on detection of a 30% difference 
in the proportions of patients in each group who reached the primary efficacy endpoint. Means, medians 
and frequency data were compared between groups using a two-tailed unpaired t-test, a Mann Whitney U, 
or Fisher’s exact test as appropriate. In the post-hoc analysis, we use a Cochrane’s Q test whether changes 
in paired frequencies differ by randomization. Because this was a phase II study with a physiological 
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endpoint, and we did not anticipate an group imbalance in patients crossing over or withdrawing, we did 
not use an intent to treat design.[21] 
 
Results 
As shown in Figure 1, from March 2014 to October 2016, we screened 1550 patients with diagnosed PE 
and obtained informed consent from 86 patients. After 8 screen failures and two voluntary withdrawals 
after starting drug (n=1) or placebo (n=1), we treated 76 patients treated per protocol (n=38 per group) for 
24 hours. Regarding timing of enrollment relative to the qualifying CT scan performance, we enrolled 32 
patients within 12 hours of CT scanning, 39 patients within 12-20 hours, 8 between 20 and 24 hours and 
one 48 hours later. 
Table 1 shows that patients were well matched for baseline vital signs, prior medical conditions and 
indexes of PE severity. The mean (SD) RV/LV ratio was 1.32 (0.39) [median 1.11, 1st-3rd quartiles 0.89-
1.69] and all 78 patients had one or more filling defects in a lobar or more proximal pulmonary artery. 
After one patient in each group withdrew after enrollment, 38 patients completed the entire protocol in 
each group (N=76 total). 
 
Primary and secondary outcomes 
Table 2 presents the primary outcome and shows that 9/38 (24%) of patients treated with NO and 5/38 
(13%) of patients treated with placebo had both normal RV function on echocardiography and a normal 
TnT after 24 hours of treatment (P=0.375, Fisher’s exact test). Analysis of the components of the primary 
outcome failed to show any salient difference between treatments; Table 2 shows relatively equal 
distribution of normal results for each the four echocardiographic variables used to define RV function. 
Figure 2, which plots the pre- and post-treatment TnT values for all patients, shows similar changes with 
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each treatment from enrollment to 24 hours. Likewise, Table 3 shows no difference in the secondary 
outcome of a BNP<90 pg/mL and the Borg dyspnea score between patients, and no difference in the 
fraction of patients who scored favorably on the psychometric tests for health related quality of life. 
Figure 3 plots the pre- and post-treatment BNP values for each patient at enrollment. Similarly, no 
difference was found in the fraction of patients who scored favorably on the psychometric tests for health 
related quality of life after 90 days (Supplemental Figure 1). Heart failure, kidney disease and coronary 
artery disease may increase steady-state concentrations of troponins and natriuretic peptides. To assess 
this possible confounding effect, we removed patients with prior heart failure, kidney disease (creatinine 
>1.7 mg/dL), and coronary artery disease, which excluded eight patients from NO treatment and five 
from placebo (supplemental Tables 1 and 2). At enrollment, mean troponin and BNP concentrations were 
elevated in patients with these comorbidities. However, as Supplemental Tables 3 and 4 show, their 
removal had no effect on the probability of normalization on either troponin T (Troponin T <14 pg/mL at 
wean: 12/30 [40%] after NO treatment versus 10/33 [30%] after placebo, P = 0.46, Fisher’s exact), or 
BNP (BNP<90 pg/mL at wean: 7/23 after NO treatment versus 10/23 after placebo, P=0.55). 
 
Safety measurements (Table 4) 
No patient was discontinued from NO for any safety reason and no serious adverse event was attributed to 
study drug. No patient had sustained methemoglobinemia (see Supplemental Figure 2).  After receiving 
intravenous promethazine and morphine, two NO-treated patients developed hypotension that required 
saline infusion. Care providers opened the blinding envelope during treatment in one placebo treated 
patient who developed worsened dyspnea. 
 
Additional clinical outcomes 
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Mortality at 28 days for patients treated with NO and Placebo respectively was 0/38 and 3/38 (P=0.24, 
Fisher’s exact) and 2/38 and 4/38 at 90 days (P=0.67). Causes of death included one death from 
complications associated with rescue embolectomy on day 3, another from respiratory failure on day 69 , 
in two, the patient died at home and the cause of death was unknown but were not ascribed to recurrent 
PE, and the other two died from progression of cancer. No patient had an autopsy at death. One patient, 
treated with placebo, had a recurrent DVT, and was the only case of VTE recurrence within 90 days. 
Supplemental figures 3-6 show the, Borg score, heart rate, SpO2%, and systolic blood pressure values at 
enrollment, 1, 8 and 24 hours of treatment. The salient observations include no apparent difference in any 
of these measurements, except for a consistently higher Borg score for NO treated patients.  
Effectiveness of study procedures 
Regarding the integrity of blinding, the clinical care physicians thought 32 patients received NO, and 
were correct in 14/32 (43%) instances; they thought 31 patients received Placebo, and were correct in 17 
(54%) instances; physicians had no opinion of treatment assignment in 13 patients. We confirmed 
evidence of NO delivery with doubling of the plasma nitrate concentration in patients treated with NO 
(Figure 4). The median nitrate concentrations (µg/mL, 1st-3rd quartiles) in the Placebo group were 15 (9-
19) and 15 (11-20) (P=0.113, sign-rank test) at enrollment and 24 hours, respectively and the median 
nitrate concentrations in the NO group were 12 (8-16) and 27 (22-38) (P<0.001, sign rank-test). Nitrite 
concentrations were not significantly changed from enrollment to 24 hours in either group. 
 
Frequency of resolution of RV hypokinesis and dilation  
This study used several echocardiographic measurements of RV function that are not commonly used in 
routine medical practice. However, we believe that RV hypokinesis and dilation are more commonly 
reported in routine echocardiographic interpretations. Accordingly, in a post-hoc analysis using only the 
71 study echocardiograms with adequate imaging to assess both RV hypokinesis and dilation, 19/35 
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(54%) of NO-treated and 10/36 (28%) of placebo-treated patients were free of either abnormality 
(P=0.03, Fisher’s exact).  Furthermore, as part of usual care, 22/38 (58%) and 24/38 (63%) of NO and 
Placebo patients, respectively had a transthoracic echocardiogram performed within 12 hours prior to 
enrollment with inadequate imaging to assess both RV hypokinesis and dilation. At enrollment, 4/22 
(18%) and 4/24 (17%) of NO and Placebo patients had neither abnormality; at 24 hours, 11/22 (50%) and 
5/24 (21%) of patients treated with NO or Placebo, respectively, were free of both abnormalities 
(P=0.010, Cochrane’s Q test).  
 
Discussion 
In this randomized, double-blind, placebo-controlled trial, the proportion of patients randomized to 24 
hours of inhaled NO who had normal RV function on echocardiography, and no evidence of myocardial 
injury (hs TnT) was not significantly higher than patients treated with placebo.  Likewise, NO treatment 
did not lower BNP concentrations, patient perceived dyspnea (Borg score), and did not improve patient 
reported health related quality of life on psychometric testing at 90 days (PEmb QoL and SF 36). The 
serial measurements of methemoglobin, dyspnea perception, heart rate, and oxygenation were not 
different between groups over the 24 hour treatment period. Study procedures appeared to reduce bias 
reasonably well. Randomization produced two groups that were similar in the distributions of prior 
cardiopulmonary disease. However, the troponin T concentrations tended to be higher in the placebo 
treated group, possibly introducing bias in favor of NO.  The Borg dyspnea score appeared to be higher at 
baseline in the NO treated group, possibly introducing bias in favor of placebo. We confirmed effective 
delivery of NO, based upon increase in plasma nitrate concentrations, similar to those measured in a 
previous trial of inhaled NO for acute chest syndrome in sickle cell disease.[22] The mechanism of 
blinding appeared effective based upon the balanced percentage of the time that clinicians correctly 
guessed which treatment the patient received. 
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The rationale for the components of each outcome were well justified.[18] The four echocardiographic 
parameters assessed the global function of the RV pumping against an acutely increased afterload: 1. The 
RV diameter to measure volume overload, 2. The TAPSE to measure longitudinal shortening, 3. The FAC 
to reflect circumferential contraction, and 4. The RIMP to indicate speed of stroke volume ejection.[23] 
The high precision troponin T was intended to measure degree of myocyte necrosis from shear effect and 
inflammatory injury, both of which increase with higher RV afterload.[24] Regarding troponin assays, we 
used troponin I as an eligibility criterion, whereas we used troponin T in the primary outcome. The reason 
for this difference was that during the time of enrollment, we used  the FDA cleared troponin assays that 
were used in usual clinical practice at the enrolling hospitals, which all measured troponin I.  The 
preplanned primary outcome required high precision troponin, and the device we used for this measures 
troponin T. In the time since our study was completed, this device has been cleared to market in the US. 
Data in Table 1 show that 14/38 (39%) of patients treated with NO normalized their troponin values, 
compared with 11/38 (29%), which if analyzed independently would have yielded P=0.63 (Fisher’s exact 
test). We do acknowledge the possibility that had we measured troponin concentrations later, for example 
at 48 hours, we may have seen wider separation in the frequency of normalization of troponin 
measurements between groups. 
 
In the secondary outcome, the plasma BNP and dyspnea severity were intended to measure RV muscle 
strain and a patient-oriented measurement of ventilation-perfusion mismatching from increased alveolar 
deadspace; moreover, these two measurements.[25]  While BNP values could have been altered by 
coincident heart failure, kidney disease or coronary artery disease, their removal had no effect on the 
proportion of patients who normalized BNP (Supplemental Tables 1-4). The two psychometric tests are 
self-evident as measures of patient perceived health wellness. We used four physiologically-oriented 
echocardiographic indexes that are not always used in usual care and can be difficult to obtain because of 
limitations in acoustic windows. For this reason, we conducted a post-hoc analysis of RV hypokinesis and 
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dilation. Our rational for choosing these two variables between NO-treated and Placebo-treated in the 
post-hoc analysis is because both variables were assessable in 93% of study echocardiograms, and RV 
hypokinesis and dilation are often reported on clinical echocardiogram interpretations. These post-hoc 
analyses suggest that NO may have improved the probability of correcting RV hypokinesis and dilation 
more than chance alone would predict. 
Taken together, these data provide some evidence of clinical value of inhaled NO for PE. On one hand, 
inhaled NO did not significantly increase the proportion of patients with good primary or secondary 
outcomes, and did not improve symptoms, heart rate, oxygenation or perception of wellness. However, 
this study does not rule out the possibility of modest improvements in RV function with inhaled NO. As a 
phase II study, the sample size was predicated on a relatively large 30% difference in primary outcome to 
justify progression to a large, expensive phase III trial. After study completion, we found an only an 11% 
difference in the primary outcome. By comparison, the only two randomized controlled trials of 
fibrinolysis versus placebo that repeated echocardiograms at 24 hours after treatment both found only a 
10% increase in rate of RV resolution compared with placebo.[26, 27]  Moreover, no NO-treated patient 
required escalation of therapy while on protocol, compared with four Placebo-treated patients, including 
two who underwent both catheter directed fibrinolysis and then surgical embolectomy (Table 4). Third, 
the post-hoc analysis suggests NO was more likely than Placebo at correcting RV hypokinesis and 
dilation at 24 hours. Finally, NO was not associated with any serious adverse events. These findings may 
leave open the possibility of future work with higher doses of NO or the use of drugs that directly 
stimulate or activate guanylate cyclase.[28] It could be speculated that NO may benefit patients with more 
severe PE, such as those with hypotension or requiring mechanical ventilation, but we believe the rarity of 
patients with this severe form of PE, combined with real world difficulty of obtaining their written 
informed consent constitute an insurmountable barrier to conducting such a trial.  
Conclusions 
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Compared with placebo, 24 hours of nasally inhaled NO did not increase the proportion of patients with 
intermediate-high risk PE who normalized their RV function, circulating troponin T or BNP 
concentrations after 24 hours of treatment. A secondary analysis suggests that inhaled NO may increase 
likelihood of resolving echocardiographically-observed RV hypokinesis and dilation. Future studies 
should focus on this endpoint. 
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Figure legends 
Figure 1.  Flow diagram showing the numbers of patients screened, consented, enrolled and treated per 
protocol 
 
Figure 2. Dot plot showing plasma concentration of troponin T at enrollment, and then again after 24 
hours of treatment for patients each treated with either placebo (n=38, squares), or 50 parts per million of 
inhaled nitric oxide (n=38, circles). The bottom panels show the median and interquartile ranges. The 
cutoff for abnormal was 14 pg/mL 
 
Figure 3. Dot plot showing plasma concentration of brain natriuretic peptide at enrollment, and then again 
after 24 hours of treatment for patients each treated with either placebo (n=38, squares), or 50 parts per 
million of inhaled nitric oxide (n=38, circles). The bottom panels show the median and interquartile 
ranges. The cutoff for abnormal was 90 pg/mL. 
 
Figure 4. Dot plot showing plasma concentration of nitrates at enrollment, and then again after 24 hours 
of treatment for patients each treated with either placebo (n=38, squares), or 50 parts per million of 
inhaled nitric oxide (n=38, circles). The bottom panels show the median and interquartile ranges.
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Table 2. The primary outcome  
Measurement Definitions 
Primary outcome Normal right ventricular function on echocardiography and normal troponin T** 
Components of primary outcome  
Right ventricular diastolic diameter < 43 mm 
Tricuspid annular plane systolic excursion >16 mm 
Right ventricular index of myocardial performance normal 
Right ventricular fractional area of contraction  >33% 
Plasma troponin T concentration <14 pg/mL 
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Table 3. Secondary outcome and mortality  
 
Measurement Definitions 
NO 
n/38
Secondary outcome Brain natriuretic peptide < 90 pg/mL and Borg dyspnea score <=2 6
Components of secondary outcome 
Brain natriuretic peptide < 90 pg/mL  13
Borg dyspnea score <=2 27
Health related quality of life (90 days) 
Favorable PEmb QoL score* 11
Favorable SF36** 15
Survival 
Mortality at 28 days 0
Mortality at 90 days 2
*Score < 40%, **Normalized score >50%; N=33, NO and N=32, Placebo; see Figure 1 for additional detail
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Table 4. Safety endpoints during treatment 
Event 
NO Placebo   
n/39* % n/39* % P value 
Unblinding 0 0% 1 3% 1.000 
Escalated to thrombolysis 0 0% 3 8% 0.240 
Escalated to thrombectomy 0 0% 1 3% 1.000 
Bleeding** 0 0% 1 3% 1.000 
Hypotension 2 5% 1 3% 1.000 
Respiratory distress requiring intervention 
METH018 – Supportive Rx: continued O2 support 
METH027 – Supportive Rx: Cpap continuation at night. 1 3% 1 3% 1.000 
Hypoxemia requiring intervention 
ESKE002 – Supportive Rx: O2 evaluation for home oxygen.  
Increase in NC flow from 4L (rest) - 6L (exertion) of O2. 
ESKE008 - Supportive Rx: O2 evaluation for home oxygen.  
Increase in NC flow from 1L (rest) - 2L (exertion) of O2. 
METH019 - Supportive Rx: O2 evaluation for home oxygen & 
discharged with home O2. 
METH028 – Supportive Rx: Bipap use at night for untreated 
sleep apnea 3 8% 1 3% 0.615 
Arrhythmia requiring intervention 
ESKE003 – Supportive Rx: Patient restarted on home 
medication, Diltiazem 30mg PO QID, due to reported A-fib with 
RVR with HR=124. 
METH014 – Supportive Rx: metoprolol started 
METH049 – Supportive Rx: Amniodarone increased from 
200mg to 600mg PO 2 5% 1 3% 1.000 
Death 0 0% 0 0% 1.000 
Other adverse event requiring medication or supportive care✝ 12 31% 10 26% 0.802 
*N=39 used in each group for denominator despite voluntary withdrawal of one subject in each group prior to 
completion of the 24 hour protocol because 39 in each group receive NO for some time period 
**Vaginal bleeding without need for transfusion or procedural intervention 
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✝Zero instances of vasopressor use, cardiopulmonary resuscitation, death bronchospasm, neurological 
deterioration, gastrointestinal distress or methemoglobinemia >10% for one hour during the 24 hour treatment 
period 
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Table 1. Clinical characteristics of enrolled patients 
Age and vital signs 
NO treated (N=39)* Placebo treated (N=39)* 
Mean SD Mean SD 
Age (years) 55 15 59 16 
Body mass index (kg/m^2) 36 12 33 11 
Heart rate (beats/min) 86 12 93 13 
Systolic blood pressure (mm Hg) 125 20 127 20 
Pulse oximetry (%) 97 3 96 6 
Patient features and past medical history N % N % 
Female gender 21 54% 20 51% 
Caucasian race 28 72% 21 54% 
Creatinine > 1.7 mg/dL 2 6% 1 3% 
Hemoglobin < 10.0 g/dL 9 26% 5 14% 
Surgery in past 4 weeks 7 18% 4 10% 
Trauma in past 4 weeks 4 10% 5 13% 
Coronary artery disease 3 8% 5 13% 
Heart failure 6 15% 1 3% 
Chronic obstructive pulmonary disease 7 18% 4 10% 
Prior venous thromboembolism 10 26% 12 31% 
Active cancer 3 8% 5 13% 
Connective tissue disease 6 15% 7 18% 
Post partum (within 4 weeks) 1 3% 1 3% 
Never smoked 25 64% 20 51% 
Markers of RV strain Median or proportion 
1st-3rd quartile 
or percentage 
Median or 
proportion  
1st-3rd quartile 
or percentage 
Troponin concentration (pg/mL) 23 12-71 51 18-101 
Brain natriuretic peptide (pg/mL) 206 83-386 234 84-556 
Right ventricular systolic pressure (mm Hg**) 54.5 50-62 50 47-52.5 
Right ventricular/Left ventricular ratio  1.12 0.89-1.69 1.10 0.85-1.68 
Right ventricular dilation (> 43 mm) on 
echocardiography 
14/24  13/26  
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Right ventricular hypokinesis on echocardiography 15/24  20/26  
*These data are for enrolled patients; one patient in each group withdrew after enrollment; **Estimated from the equation V^2*4 + 10 
mm Hg where V= tricuspid regurgitant jet velocity (meters/second)  
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Highlights 
Patients with intermediate risk pulmonary embolism were randomized to 24 hours of inhaled nitric 
oxide (N), delivered by nasal cannula, or oxygen placebo . The primary outcome was a normal right 
ventricle on echocardiography and a normal high sensitivity troponin measurement. 
Patients who received NO were not more likely to reach the primary outcome. NO treatment also did 
not increase the proportion of patients with a normal brain natriuretic peptide. 
A post-hoc analysis showed that patients who had RV hypokinesis on echocardiography at enrollment 
who were treated with NO were more likely to resolve their hypokinesis, compared with patients 
treated with placebo. 
